Skip to content

Tanden, former OMB nominee, to become senior Biden adviser

Porfolio reportedly will include health care, U.S. Digital Service

CAP President and CEO Neera Tanden will be a senior White House adviser.
CAP President and CEO Neera Tanden will be a senior White House adviser. (Bill Clark/CQ Roll Call file photo)

Neera Tanden, the president and CEO of the Center for American Progress, will become a senior adviser to President Joe Biden, a White House official confirmed Friday.

Tanden, whose nomination to be director of the Office of Management and Budget was withdrawn in early March after it became clear she did not have sufficient support to win Senate confirmation, had been expected to take a senior administration role that does not require advice and consent.

“Neera’s intellect, tenacity, and political savvy will be an asset to the Biden administration as she assumes a new role as Senior Advisor to the President,” CAP founder John Podesta said in a statement.

CNN reported that Tanden’s policy portfolio will include reviewing the U.S. Digital Service, a White House-based information technology improvement team, as well as preparations for possible fallout from court decisions related to GOP legal challenges to the 2010 health care law.

Shalanda Young, the deputy director of OMB, has been serving as acting director. She is a former staff director and clerk for the Democrats on the House Appropriations Committee.

The full release of the president’s budget proposal for fiscal 2022 is now scheduled for May 27, and Young is likely to be front-and-center for that process. Biden has not nominated anyone for the position of director.

Recent Stories

GOP readies bills to fund or authorize White House ballroom

One idea to retain Capitol Police officers? Up the retirement age

California man charged in White House media gala shooting

Bipartisan bill would study maternal health-violence link

DeSantis unveils new map aiming to help Florida GOP flip 4 House seats

Immigration debate, upfront costs are hurdles for hepatitis C bill